<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="was further investigated in downstream studies. The inhibitory activities of" exact="bortezomib" post="were confirmed using different cellular models and CHIKV strains."/>
 <result pre="models and CHIKV strains. Time-of-addition and time-of-removal studies suggested that" exact="bortezomib" post="inhibited CHIKV at an early, post-entry stage of replication."/>
 <result pre="an early, post-entry stage of replication. In western blot analysis," exact="bortezomib" post="treatment resulted in a prominent decrease in structural protein"/>
 <result pre="protein ratios potentially being a contributing factor. Proteasome inhibitors like" exact="bortezomib" post="likely disrupt CHIKV replication through a variety of complex"/>
 <result pre="into its antiviral mechanism. We confirmed the anti-CHIKV effects of" exact="bortezomib" post="using different cell lines and CHIKV strains. We found"/>
 <result pre="using different cell lines and CHIKV strains. We found that" exact="bortezomib" post="resulted in a major decrease in levels of CHIKV"/>
 <result pre="increased CHIKV RNA synthesis. We propose that proteasome inhibitors like" exact="bortezomib" post="are likely to inhibit CHIKV through various mechanisms that"/>
 <result pre="a post-entry step in the CHIKV replication cycle. Treatment with" exact="bortezomib" post="also resulted in a decrease in structural protein expression."/>
 <result pre="effects of proteasome inhibitors, we tested the inhibitory potential of" exact="bortezomib" post="using CHIKV-infected BHK21 cells in both post-treatment and pre-treatment"/>
 <result pre="with bortezomib. This was performed to establish the effects of" exact="bortezomib" post="on post-entry steps. As seen in Fig 1A, treatment"/>
 <result pre="steps. As seen in Fig 1A, treatment with 0.1 μM" exact="bortezomib" post="onwards resulted in significant inhibition of CHIKV infectious titer."/>
 <result pre="1A), indicating minimal toxicity. In fact, treatment with 0.1 μM" exact="bortezomib" post="produced 97% (1.5 log10 units) inhibition with no decrease"/>
 <result pre="was also carried out, where BHK21 cells were treated with" exact="bortezomib" post="for 2 hours, washed with PBS and then immediately"/>
 <result pre="then immediately infected with CHIKV. This was to determine whether" exact="bortezomib" post="could affect the cells in a way that hindered"/>
 <result pre="entry. The inhibitory trend was not observed upon pre-treatment with" exact="bortezomib" post="(Fig 1B). Collectively, this data suggests that the anti-CHIKV"/>
 <result pre="1B). Collectively, this data suggests that the anti-CHIKV effects of" exact="bortezomib" post="are likely to occur at a post-entry stage in"/>
 <result pre="post-entry stage in the replication cycle. Fig 1 Effects of" exact="bortezomib" post="treatment on CHIKV infection in BHK21 cells. (A) BHK21"/>
 <result pre="were infected with CHIKV-122508 and treated with indicated concentrations of" exact="bortezomib" post="for 24h. CHIKV titers are presented in the bar"/>
 <result pre="control). (B) In pre-treatment assays, BHK21 cells were treated with" exact="bortezomib" post="for 2h, washed and infected with CHIKV-122508 at MOI"/>
 <result pre="to its inhibitory effects on macromolecular synthesis [39]. Treatment with" exact="carfilzomib" post="(Fig 2E) and oprozomib (Fig 2H) resulted in decreasing"/>
 <result pre="of (A) MG-132, (B) MLN-9708 (C) MLN-2238, (D) delanzomib, (E)" exact="carfilzomib" post="(F) ONX-0914, (G) epoxomicin, (H) oprozomib (I) lactacystin and"/>
 <result pre="comparing proteasome inhibitor-treated samples to vehicle control). Inhibitory effects of" exact="bortezomib" post="across different CHIKV strains and cell lines In order"/>
 <result pre="observed were not due to cell-line- or CHIKV strain-dependent effects," exact="bortezomib" post="was tested in two additional cell lines (HeLa and"/>
 <result pre="HSMM) and against two strains of CHIKV. In HeLa cells," exact="bortezomib" post="treatment resulted in a dose-dependent reduction of titer for"/>
 <result pre="with CHIKV-122508 and CHIKV-0708, respectively (Fig 3A). The efficacy of" exact="bortezomib" post="was also confirmed in primary human skeletal myoblasts (HSMM),"/>
 <result pre="in HSMM cells was inhibited in a dose-dependent manner upon" exact="bortezomib" post="treatment (Fig 3B). A maximal inhibition of 1.5 log10"/>
 <result pre="of &amp;gt;106 PFU/ml were obtained. Fig 3 Inhibitory effects of" exact="bortezomib" post="on different CHIKV strains and cell lines. (A) HeLa"/>
 <result pre="cells were infected with CHIKV-122508 or CHIKV-0708 and post-treated with" exact="bortezomib" post="for 24h. CHIKV titers are presented in the bar"/>
 <result pre="(B) HSMM cells were infected with CHIKV-122508 and post-treated with" exact="bortezomib" post="for 24h. CHIKV titers are presented in the bar"/>
 <result pre="ANOVA test and Dunnett’s post-test. 10.1371/journal.pntd.0008336.t001Table 1 Selectivity indices of" exact="bortezomib" post="treatment in BHK, HeLa and HSMM cells infected with"/>
 <result pre="to identify the window in the CHIKV replication cycle where" exact="bortezomib" post="exerts its effects. As displayed in the schematic diagram"/>
 <result pre="diagram in Fig 4A, time-of-addition experiments were performed by adding" exact="bortezomib" post="at different time-points post-infection, while time-of-removal experiments were conducted"/>
 <result pre="different time-points post-infection, while time-of-removal experiments were conducted by adding" exact="bortezomib" post="immediately after infection and removing it at different time-points"/>
 <result pre="time-points (0, 2, 4 hpi) are shown. For time-of-addition studies," exact="bortezomib" post="was added at different time-points post-infection. For time-of-removal studies,"/>
 <result pre="bortezomib was added at different time-points post-infection. For time-of-removal studies," exact="bortezomib" post="was added at 0h post-infection and then removed at"/>
 <result pre="harvested at 48 hpi. Dotted lines represent the duration of" exact="bortezomib" post="treatment. (B) CHIKV titers from time-of-addition and time-of-removal assays."/>
 <result pre="means from at least 4 replicates. The antiviral effect of" exact="bortezomib" post="was most pronounced when it was added at early"/>
 <result pre="inhibited (Fig 4B). The time-of-removal experiment revealed that removal of" exact="bortezomib" post="at 16 hpi or earlier prevented its inhibitory effects"/>
 <result pre="inhibitory effects (Fig 4B). Furthermore, time-of-removal studies also showed that" exact="bortezomib" post="treatment for the first 16h was necessary before its"/>
 <result pre="in structural protein levels We next evaluated the possibility that" exact="bortezomib" post="affects CHIKV RNA synthesis and/or viral RNA translation events."/>
 <result pre="time-points post-infection in HeLa cells. As shown in Fig 5," exact="bortezomib" post="treatment resulted in a striking decrease of about 50"/>
 <result pre="in a dose-dependent manner upon treatment with different concentrations of" exact="bortezomib" post="at 6 hpi (Fig 6). Fig 5 Time-point studies"/>
 <result pre="6). Fig 5 Time-point studies of CHIKV protein levels upon" exact="bortezomib" post="treatment. HeLa cells were infected with CHIKV-122508 and treated"/>
 <result pre="were infected with CHIKV-122508 and treated with either 0.1 μM" exact="bortezomib" post="or vehicle control. Protein samples were harvested at different"/>
 <result pre="protein). Fig 6 Dose-dependent studies of CHIKV protein levels upon" exact="bortezomib" post="treatment at 6 hpi. HeLa cells were infected with"/>
 <result pre="were infected with CHIKV-122508 and treated with either 0.1 μM" exact="bortezomib" post="or vehicle control. Protein samples were harvested at 6"/>
 <result pre="and nsP3 was observed upon treatment with increasing concentrations of" exact="bortezomib" post="(Fig 6). These fluctuations suggest that bortezomib may affect"/>
 <result pre="increasing concentrations of bortezomib (Fig 6). These fluctuations suggest that" exact="bortezomib" post="may affect structural and ns proteins in different ways,"/>
 <result pre="Western blot analysis showed major elevations in nsP4 levels upon" exact="bortezomib" post="treatment, especially at early time-points of 6 and 8"/>
 <result pre="(Fig 4B), which showed that the maximal inhibitory effect of" exact="bortezomib" post="was observed when added between 0 to 8 hpi."/>
 <result pre="transcripts for subsequent translation [47]. To understand the effects of" exact="bortezomib" post="treatment on eIF2α phosphorylation in CHIKV-infected cells, the levels"/>
 <result pre="eIF2α were measured in time-point studies. Fig 8 shows that" exact="bortezomib" post="treatment of CHIKV-infected HeLa cells caused a general reduction"/>
 <result pre="time, with relatively stable levels of total eIF2α. Strikingly, however," exact="bortezomib" post="treatment in mock-infected cells also resulted in reduced phospho-eIF2α"/>
 <result pre="bortezomib. Fig 8 Changes in total and phospho-eIF2α levels upon" exact="bortezomib" post="treatment. (A) HeLa cells were infected with CHIKV-122508 and"/>
 <result pre="were infected with CHIKV-122508 and treated with either 0.1 μM" exact="bortezomib" post="or vehicle control. Protein samples were harvested at different"/>
 <result pre="CHIKV ns protein levels, we also evaluated the effects of" exact="bortezomib" post="on CHIKV RNA levels. Bortezomib treatment increased total CHIKV"/>
 <result pre="at 12 hpi and 24 hpi (Fig 9B), suggesting that" exact="bortezomib" post="induces similar effects on replication of both CHIKV strands."/>
 <result pre="it is clear that the major direct antiviral effect of" exact="bortezomib" post="stems from its effect on suppressing structural protein levels,"/>
 <result pre="extensive study. Fig 9 Changes in CHIKV RNA levels upon" exact="bortezomib" post="treatment. HeLa cells were infected with CHIKV-122508 and treated"/>
 <result pre="were infected with CHIKV-122508 and treated with either 0.1 μM" exact="bortezomib" post="or vehicle control. Samples were harvested at different time-points"/>
 <result pre="and negative-sense CHIKV RNA. The major direct antiviral effect of" exact="bortezomib" post="is likely to result from its effect on suppressing"/>
 <result pre="in different ways. In previous studies, the antiviral effects of" exact="bortezomib" post="has been attributed to a number of different mechanisms."/>
 <result pre="mechanisms. In cells infected with Rift Valley Fever virus (RVFV)," exact="bortezomib" post="reduced the ability of the non-structural S-segment protein (NSs)"/>
 <result pre="with thrombocytopenia syndrome virus (SFTSV), a phlebovirus related to RVFV," exact="bortezomib" post="treatment reversed the degradation of RIG-I induced by the"/>
 <result pre="[24]. In our study, the increase in nsP4 levels upon" exact="bortezomib" post="treatment suggests that the CHIKV nsP4, like that of"/>
 <result pre="and nsP3 may be due to multiple competing effects of" exact="bortezomib" post="on these proteins. For instance, bortezomib may either increase"/>
 <result pre="multiple competing effects of bortezomib on these proteins. For instance," exact="bortezomib" post="may either increase nsP2/nsP3 expression or reduce their degradation,"/>
 <result pre="their levels within infected cells. However, by reducing virion production," exact="bortezomib" post="also restricts viral spread in the monolayer, reducing the"/>
 <result pre="hpi, despite increased nsP4 levels from 6 hpi onwards. While" exact="bortezomib" post="caused some increase in ns protein levels, structural protein"/>
 <result pre="and significantly decreased at all time-points. This may suggest that" exact="bortezomib" post="may affect SG RNA translation differently from G RNA"/>
 <result pre="G and SG RNA may explain the different effects of" exact="bortezomib" post="on CHIKV ns and structural proteins. A similar phenomenon"/>
 <result pre="similar possibility. In dose-dependent studies, treatment with 0.025 μM of" exact="bortezomib" post="caused CHIKV nsP3 levels to increase by about 30%"/>
 <result pre="concentrations. The alterations in ns and structural protein levels upon" exact="bortezomib" post="treatment also reflect a similar phenotype recently described for"/>
 <result pre="changes in their ratio, similar to what is observed during" exact="bortezomib" post="treatment, would have a negative impact on viral replication."/>
 <result pre="of proteasome inhibitors also inhibit other cellular proteases. For instance," exact="bortezomib" post="exhibits off-target activity against some intracellular proteases, including cathepsins"/>
 <result pre="from western blot studies showed that proteasome inhibitors apart from" exact="bortezomib" post="caused similar changes to CHIKV proteins, suggesting a common"/>
 <result pre="contributors to their inhibitory effects. Whether the antiviral effects of" exact="bortezomib" post="are a result of inhibition of translation of SG"/>
 <result pre="be used as CHIKV antivirals is warranted. A limitation of" exact="bortezomib" post="is its narrow therapeutic window [61]. In cancer patients,"/>
 <result pre="within two weeks. Furthermore, altering the route of administration of" exact="bortezomib" post="from intravenous to subcutaneous has been found to significantly"/>
 <result pre="a similar method could be employed to limit toxicity of" exact="bortezomib" post="and other proteasome inhibitors in the context of CHIKV"/>
 <result pre="pre-treatment assay was also performed, where cells were treated with" exact="bortezomib" post="prior to infection with CHIKV. BHK21 monolayers were incubated"/>
 <result pre="with CHIKV. BHK21 monolayers were incubated with various concentrations of" exact="bortezomib" post="for 2h at 37°C before being washed twice with"/>
 <result pre="-80°C prior to performing plaque assays for titration. Validation of" exact="bortezomib" post="activity in HeLa and HSMM Post-treatment experiments similar to"/>
 <result pre="[68]. After the washing step, infected cells were incubated with" exact="bortezomib" post="at various concentrations for 48h (HeLa) or 24h (HSMM)"/>
 <result pre="plaque assays. In order to measure the therapeutic window of" exact="bortezomib" post="in CHIKV-infected HeLa cells, the selectivity index (SI) was"/>
 <result pre="cytotoxic concentration) to EC50 (50% effective concentration). The EC50 of" exact="bortezomib" post="in HeLa cells was defined as the concentration of"/>
 <result pre="bortezomib in HeLa cells was defined as the concentration of" exact="bortezomib" post="required to reduce virus titer by 50%. The CC50"/>
 <result pre="by 50%. The CC50 was defined as the concentration of" exact="bortezomib" post="required to reduce cell viability by 50%. Cell viability"/>
 <result pre="and washed twice with PBS. For time-of-addition experiments, 0.1 μM" exact="bortezomib" post="was added at different time-points after the 1.5h infection"/>
 <result pre="different time-points after the 1.5h infection period. In time-of-removal experiments," exact="bortezomib" post="was added immediately after the 1.5h infection period and"/>
 <result pre="Studio programme. Measurement of changes in CHIKV RNA levels upon" exact="bortezomib" post="treatment HeLa cells were seeded on 24-well plates (80,000"/>
 <result pre="3 times with PBS before being incubated with 0.1 μM" exact="bortezomib" post="or vehicle control. Cells were washed once with PBS"/>
 <result pre="2013;73(1):45–54. 10.1007/s40265-013-0006-623338539 38BuacD, ShenM, SchmittS, KonaFR, DeshmukhR, ZhangZ, et al.From" exact="bortezomib" post="to other inhibitors of the proteasome and beyond.Curr Pharm"/>
 <result pre="ParlatiF, ShenkKD, LeeSJ, et al.Nonproteasomal targets of the proteasome inhibitors" exact="bortezomib" post="and carfilzomib: a link to clinical adverse events. Clin"/>
</results>
